

VPA10387/059/001

Rimadyl Palatable Tablets 20 mg

Variation	Summary	Date
Vet - B12 b)	VNRA - Vet - B12 b) - b) Minor changes to an approved test procedure (starting material, excipient) - B12 b) Changes to the quality part of the dossier: Minor changes — to an approved test procedure — for a starting material, reagent or intermediate used in the manufacturing process of the active substance; — for an excipient	25/03/25
Vet - B12 a)	VNRA - Vet - B12 a) - a) Minor changes to an approved test procedure (active, finished product, packaging, measuring device) - B12 a) Changes to the quality part of the dossier: Minor changes — to an approved test procedure — for active substance; — for the finished product; — for the immediate packaging of the active substance or the finished product; — of a measuring or administration device	24/03/25
Vet - B12 a)	VNRA - Vet - B12 a) - a) Minor changes to an approved test procedure (active, finished product, packaging, measuring device) - B12 a) Changes to the quality part of the dossier: Minor changes — to an approved test procedure — for active substance; — for the finished product; — for the immediate packaging of the active substance or the finished product; — of a measuring or administration device	21/02/25
Vet - F.I.a.2 d)	VRA-R - Vet - F.I.a.2 d) - d) Minor change to the restricted part of an Active Substance Master File - F.I.a.2 d) Quality Changes - Active Substance - Manufacture - Changes in the manufacturing process of the active substance - Minor change to the restricted part of an Active Substance Master File	21/02/25
Vet - B34	VNRA - Vet - B34 - Change in qualitative and quantitative composition of the immediate packaging for a solid pharmaceutical form for a finished product - B34 Changes to the quality part of the dossier: Change in qualitative and quantitative composition of the immediate packaging for a solid pharmaceutical form for a finished product	20/12/24
Vet - F.I.f.1	VRA-S - Vet - F.I.f.1 - 1. Substantial changes in the updated version of the ASMF or the active substance part of the dossier - F.I.f.1 Quality Changes - Active Substance - Other changes to the active substance - Substantial changes in the updated version of the ASMF or the active substance part of the dossier	10/06/24
Vet - B3 a)	VNRA - Vet - B3 a) - a) Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier) - B3 a) Changes to the quality part of the dossier: Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for	07/07/23

	batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier)	
B.II.e.1.a.1	IA - B.II.e.1.a.1 - 1. Solid pharmaceutical forms - B.II.e.1.a.1 - QUALITY CHANGES - FINISHED PRODUCT - Container closure system - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms	08/02/22
B.II.e.1.a.1	IA - B.II.e.1.a.1 - 1. Solid pharmaceutical forms - B.II.e.1.a.1 - QUALITY CHANGES - FINISHED PRODUCT - Container closure system - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms	08/02/22
B.II.e.4.a	IA - B.II.e.4.a - a) Non-sterile medicinal products - B.II.e.4.a - QUALITY CHANGES - FINISHED PRODUCT - Container closure system - Change in shape or dimensions of the container or closure (immediate packaging) - Non-sterile medicinal products	08/02/22